LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

571.02 -1.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

567.68

Max

579.14

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-89M 275M
Pardavimai	-8.7M 782M
P/E Sektoriaus vid.	21.006 50.102
Pelnas, tenkantis vienai akcijai	5.82
Pelno marža	35.176
Darbuotojai	1,400
EBITDA	-176M 348M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+13.56% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-537M 24B
Ankstesnė atidarymo kaina	572.25
Ankstesnė uždarymo kaina	571.02

Naujienos nuotaikos

By Acuity

34%

66%

78 / 344 reitingas Healthcare

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-26 16:52; UTC

Svarbiausios naujienos

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q Rev $1.76B >SQM

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q EPS $1.28 >SQM

2026-05-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q EPS $11.61 >WEBC

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q Sales $179.6M >WEBC

2026-05-26 21:48; UTC

Rinkos pokalbiai

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026-05-26 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-05-26 20:58; UTC

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026-05-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 19:22; UTC

Rinkos pokalbiai

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026-05-26 19:17; UTC

Rinkos pokalbiai

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026-05-26 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026-05-26 18:03; UTC

Rinkos pokalbiai

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026-05-26 17:42; UTC

Rinkos pokalbiai

Grains Await Fresh Trading Catalyst -- Market Talk

2026-05-26 17:33; UTC

Rinkos pokalbiai

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026-05-26 17:21; UTC

Rinkos pokalbiai

Canada Faces a Labor Market Squeeze -- Market Talk

2026-05-26 16:52; UTC

Rinkos pokalbiai

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026-05-26 16:43; UTC

Rinkos pokalbiai

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026-05-26 16:24; UTC

Rinkos pokalbiai

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026-05-26 16:21; UTC

Rinkos pokalbiai

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-05-26 16:16; UTC

Rinkos pokalbiai

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026-05-26 16:01; UTC

Rinkos pokalbiai

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026-05-26 15:21; UTC

Rinkos pokalbiai

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

13.56% į viršų

12 mėnesių prognozė

Vidutinis 656.85 USD 13.56%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

78 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.